Lim CY, Liu X, He F, et al. - A retrospective cohort study was performed to evaluate the advantages of denosumab in combination with nerve-sparing surgery for treatment of sacral giant cell tumours (GCTs). Researchers recruited a total of 68 individuals with GCT between January 2011 and July 2017. Intralesional curettage was conducted and individuals treated from 2015 to 2017 also received denosumab therapy. Individuals were categorized into three groups: Cohort 1: control group (n = 36); cohort 2: adjuvant denosumab group (n = 9); and cohort 3: neo- and adjuvant-denosumab group (n = 17). The reduction of intraoperative haemorrhage was noted by preoperative denosumab therapy and was correlated with shorter operating times. After surgery, adjuvant denosumab was beneficial to prevent early recurrence during the first two years.